




WORLD CONGRESS ON Gastrointestinal Cancer



**Groundbreaking
Research + Education**

**3-6 July 2019
Barcelona
SPAIN**

worldgicancer.com

AN **IMEDEX** EVENT
AN hmp COMPANY

Distinguished Pioneers.

Cutting-Edge Technology.

Educational Excellence.

Join us for the world-renowned gathering of more than 3.500 professionals dedicated to transforming the field of gastrointestinal cancer. Through captivating presentations and case studies, provocative panel discussions, and interactive debates, we'll be one step closer to discovering a cure for GI cancer and refining optimal treatment for patient care.



CHAIR

Mario Dicato

Luxembourg, Luxembourg



CHAIR

Eric Van Cutsem

Leuven, Belgium



VICE CHAIR


Josep Tabernero

Barcelona, Spain

3.500+ Delegates

120+ Countries


20+ Sessions



ADJUVANT TREATMENT TRENDS IN PANCREATIC ADENOCARCINOMA PATIENTS

Antonella Nardeschia¹, Mario Roselli²

¹Intestinal Medical Oncology and Neuroendocrine
²Oncology



INTRODUCTION

- Nab-paclitaxel (nab-P, Abraxane®, Celgene) plus gemcitabine (nab-P/G) has proven tolerability and superior efficacy as first-line treatment for metastatic pancreatic cancer (mPC) compared to alone in the MPACT randomized phase III trial.^{1,2}
- In clinical practice, however, is comprised of diverse treatment heterogeneous patient populations.

18,239 mPC pts were included in

summarized in Table 1.

pts	≤ 70 years	> 70 years
All patients (n=239)	(n=130)	(n=109)
70 (44.8%)	64 (44.7%)	75 (71.1%)
131 (55%)	70 (53%)	62 (5.5%)
(n=223)	(n=125)	(n=98)

Scientific Committee

Fatima Carneiro

Ipatimup and Medical
Faculty
Porto, Portugal

Andrés Cervantes

INCLIVA Biomedical
Research Institute
University of Valencia
Valencia, Spain

Fortunato Ciardiello

Università degli Studi della
Campania Luigi Vanvitelli
Caserta, Italy

Mario Dicato

Congress Chair
Luxembourg Medical Center
Luxembourg, Luxembourg

Michel Ducreux

Institut Gustave Roussy
Paris, France

Jorge Gallardo

Chilean Foundation for
Oncology Development
Santiago, Chile

Sharlene Gill

University of British
Columbia
Vancouver, Canada

Karin Haustermans

University Hospital
Gasthuisberg
Leuven, Belgium

David H. Ilson

Memorial Sloan Kettering
Cancer Center
New York, New York, United
States

Brigette Ma

Chinese University
of Hong Kong
Hong Kong, Hong Kong

Erika Martinelli

Università degli Studi della
Campania Luigi Vanvitelli
Caserta, Italy

Philip A. Philip

Karmanos Cancer Institute
Detroit, Michigan, United
States

Jaroslav Regula

Maria Skłodowska Curie
Memorial Cancer Centre and
Institute of Oncology
Warsaw, Poland

Rachel Riechelmann

AC Camargo Cancer Center
São Paulo, Brazil

Thomas Seufferlein

Ulm University
Ulm, Germany

Ali Shamseddine

American University of Beirut
Medical Center
Beirut, Lebanon

Alberto Sobrero

IRCCS Ospedale San
Martino IST
Genova, Italy

Josep Tabernero

Congress Vice Chair
ESMO President 2018–2019
Vall d'Hebron University
Hospital
Barcelona, Spain

Eric Van Cutsem

Congress Chair
University Hospital
Gasthuisberg
Leuven, Belgium

Takayuki Yoshino

National Cancer Center
Hospital East
Chiba, Japan

Agenda

The following topics will be presented through didactic lectures, tandem talks, debates, keynote lectures, and selected abstract presentations:

Cancer of the Pancreas

- Genetics and molecular alterations in pancreatic cancer
- How far can and should a surgeon go in borderline resectable pancreatic cancer?
- Adjuvant and neoadjuvant treatment of pancreatic cancer in resectable pancreatic cancer
- The optimal strategy in locally advanced unresectable pancreatic cancer

Bile Duct Cancer

- Molecular alterations in bile duct cancer
- New agents/strategies on the horizon in bile duct cancer

Meet the Expert Presentations

- New endoscopic screening tools: Narrow band imaging, chromoendoscopy – How do they help us?
- Advances in surgery of rectal cancer
- The malignant colorectal polyp
- Progress in anal cancer
- Carcinoma of unknown origin
- How to classify NETs and NECs
- ESMO Session: Focus on young medical oncologists

Studying Value and Validity in Oncology

- Studying value and health economics in GI cancer
- Interpretation and validity of clinical trials: When do they become practice-changing?
- Validity of real-world evidence
- Studying biosimilars: What is needed and what is the role of biosimilars?

Esophageal and Gastric Cancers

- Unraveling the molecular taxonomy in oesophageal and gastric cancer
- Barrett esophagus: Role of advanced endoscopy in the diagnosis and treatment
- Management of squamous cell cancer for the esophagus
- Locally advanced GE junction cancer
- Hereditary gastric cancer syndromes
- Endoscopic treatment of gastric cancer
- Surgery in oligometastatic gastric cancer

Relevant Pathways in GI Cancer: How Relevant and How to Approach Them

- The HER-2 pathway
- DNA repair mechanisms and pathways
- NGS testing for all patients with GI cancers?

Hepatocellular Carcinoma

- How to integrate new agents in HCC
- Locoregional treatment for HCC
- Multidisciplinary tumor board on HCC

Expert Highlights: What is New in this Disease in 2019?

- What is new in non-pancreatic NET?
- What is new in pancreatic NET?
- What is new in anal cancer?
- What is new on debulking and HIPEC in peritoneal carcinomatosis in the last 12 months?

Demographics and GI Cancer

- How relevant are the tools for geriatric assessment in GI cancers?
- Is gender relevant for decision-making in the management of GI cancer?

Multimodality Therapy for Rectal Cancer

- How to perform and interpret an MRI in rectal cancer
- Surgery or watchful waiting when a complete response is achieved in rectal cancer?
- How to prevent local recurrence in enlarged lymph nodes
- Adjuvant chemotherapy in rectal cancer or introduce more neoadjuvant chemotherapy
- The strategy in synchronous liver metastases of rectal cancer



Molecular Biology in CRC

- How to approach the patient with a BRAF mutant tumor
- Molecular classification of colon cancer: New insights
- Should DPD deficiency be searched before starting 5FU?
- MSI testing in all patients and how to test

Keynote Lectures

- The microbiome in GI cancers: How relevant is it?
- Anticoagulation in GI cancer patients
- How to look for minimal residual disease

Multidisciplinary Tumor Boards

- Molecular and hereditary tumor board
- The challenging patient with HCC
- The challenging patient with colorectal cancer

Immune Mechanisms and Immune Therapy in GI Cancer

- How to improve the results with IO agents in MSI GI cancer
- Novel immune oncology mechanisms and approaches in GI cancers: Where are we?
- Can we increase the immunogenicity in MSS CRC?
- The link between the immune microenvironment and outcome in colorectal cancer

Colorectal Cancer

- Updates on treatment algorithms in metastatic CRC in 2019
- Chemorefractory colorectal cancer
- New drugs on the horizon: Can we refine the selection for adjuvant treatment in stage III colon cancer?

Clinical Updates

- When and how to select for debulking and HIPEC in peritoneal carcinomatosis
- Liver resection of liver metastases

“We invite you to join the ESMO World GI 2019 Congress, which is the premier event on GI cancers. You can enjoy the most relevant, new scientific data, top education, and stimulating discussions amongst experts and peers. This congress is a must for everybody involved in GI cancer research and/or clinical care and helps you in your clinical practice and your research projects.”

– Eric Van Cutsem, Chair



“The explosion of information in cancer medicine, flooding the practicing oncologist, has made it impossible to cover the field and has led over the past decades to organ-oriented cancer meetings. With my two colleagues, I am happy to have initiated this gastrointestinal cancer congress 21 years ago. Here, interested participants can get all the GI cancer-related pertinent clinical and basic science information in a couple of days, in the pleasant environment of Barcelona.” —**Mario Dicato, Chair**

If you're involved in the treatment of gastrointestinal cancers,

THIS MEETING IS FOR YOU.

- Gastrointestinal and Medical Oncologists
- Gastroenterologists/Hepatologists
- Pathologists
- Abdominal Surgeons
- Radiation Oncologists
- Clinicians & Researchers
- Healthcare Professionals Involved in GI cancer

Continuing Education



Imedex has submitted an application for the ESMO World Congress on Gastrointestinal Cancer to award ESMO-MORA points. All participants will receive a certificate of participation at the end of the Congress. Recertification is necessary for those medical oncologists who wish to remain professionally certified by the European Society of Medical Oncology. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology.

Who Should Attend

This Congress is specifically designed for practicing clinicians, gastroenterologists, hepatologists, pathologists, surgeons, medical oncologists, radiation oncologists, and clinical researchers who wish to review and update their knowledge and management of cancers of the gastrointestinal tract.

Learning Objectives

After attending this Congress, participants should be able to:

- Identify controversies in the management of patients with gastric or esophageal cancers
- Discuss contemporary treatment options for patients with gastric or esophageal cancers
- Comment on available treatment options for rare gastrointestinal and neuroendocrine tumors
- Describe the epidemiology, pathogenesis, and management of hepatocellular carcinoma
- Identify adjuvant and neoadjuvant treatment options for patients with locally advanced and metastatic cancer of the pancreas
- Select the most appropriate detection, screening, and methods for colorectal cancer
- Select the most appropriate adjuvant and neoadjuvant treatments for colorectal cancer patients
- Comment on new agents in the treatment of colorectal cancer, other GI cancers, and the latest clinical trials results
- Identify treatment strategies for rectal cancer
- Distinguish appropriate surgical techniques for the treatment of gastrointestinal cancer
- Understand the role of molecular markers in GI cancer
- Understand immunomechanisms involved in GI cancer
- Understand pharmacoeconomic principles involved in GI cancer

Register online at
worldgicancer.com
or call +1 678.242.0906

REGISTER BY 14 JUNE 2019 FOR
THE BEST RATES.

VIEW HOTELS
AND RESERVE
YOUR ROOM
ONLINE

WWW.
worldgicancer.
com/hotel

REGISTRATION RATES

	NON-MEMBER RATE	ESMO MEMBER RATE*
EARLY Before 17 May 2019		
Physician	€700	€560
PhD, PharmD	€615	€490
Nurse, Student, Trainee, Fellow, Resident, Nurse Practitioner, Physician Assistant*	€400	€320
DISCOUNTED Before 14 June 2019		
Physician	€800	€640
PhD, PharmD	€715	€570
Nurse, Student, Trainee, Fellow, Resident, Nurse Practitioner, Physician Assistant*	€450	€360
REGULAR After 14 June 2019		
Physician	€950	€760
PhD, PharmD	€865	€690
Nurse, Student, Trainee, Fellow, Resident, Nurse Practitioner, Physician Assistant*	€525	€420
Pharmaceutical Industry Representative	€950	

**Proof of eligibility may be required.*



CONGRESS LOCATION

The International Convention Center of Barcelona
Centre de Convenciones Internacional de Barcelona (CCIB)
Placa de Willy Brandt 11-14
08019 Barcelona, Spain

RESERVE YOUR PLACE TODAY



WORLD CONGRESS ON
Gastrointestinal
Cancer

| AN **IMEDEX** EVENT | 11675 Reinwater Drive, Suite 600
Alpharetta, GA 30009, USA



3-6 July 2019
Barcelona SPAIN

LATE REGISTRATION DEADLINE
14 JUNE 2019

worldgicancer.com